Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

Neurobiology of Disease

Volumn 25, Issue 1, 2007, Pages 134-149

  Chu, Yaping ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aging; Dopaminergic neuron; Substantia nigra; Synuclein; Synucleinopathy; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE;

ADULT; AGED; AGING; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; FEMALE; HUMAN; HUMAN TISSUE; LYSOSOME; MALE; MONKEY; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; TEGMENTUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CELL COUNT; DOPAMINE; ENDOPEPTIDASE K; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACACA MULATTA; MALE; MELANINS; MESENCEPHALON; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33751118534     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.08.021     Document Type: Article

References (73)

1. Andersen A.H., Zhang Z., Zhang M., Gash D.M., and Avison M.J. Age-associated changes in rhesus CNS composition identified by MRI. Brain Res. 829 (1999) 90-98
2. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 (2002) 865-868
3. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., and Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55 (2000) 1358-1363
4. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., and Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38 (2006) 515-517
5. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2002) 256-259
6. Chu Y., Kompoliti K., Cochran E.J., Mufson E.J., and Kordower J.H. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol. 450 (2002) 203-214
7. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E.J., and Kordower J.H. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 494 (2006) 495-514
8. Collier T.J., Ling Z.D., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek Jr. J.R., and Kordower J.H. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp. Neurol. 191 Suppl. 1 (2005) S60-S67
9. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., and Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004) 1292-1295
10. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
11. Dawson Jr. R., Pelleymounter M.A., Cullen M.J., Gollub M., and Liu S. An age-related decline in striatal taurine is correlated with a loss of dopaminergic markers. Brain Res. Bull. 48 (1999) 319-324
12. Drolet R.E., Behrouz B., Lookingland K.J., and Goudreau J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25 (2004) 761-769
13. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., Holden J.E., and Kordower J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401 (1998) 253-265
14. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev., Genet. 7 (2006) 306-318
15. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
16. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
17. Frielingsdorf H., Schwarz K., Brundin P., and Mohapel P. No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10177-10182
18. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., and Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34 (2002) 521-533
19. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., and Pakkenberg B. The new stereological tools: dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96 (1988) 857-881
20. Hayashita-Kinoh H., Yamada M., Yokota T., Mizuno Y., and Mochizuki H. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 341 (2006) 1088-1095
21. Iwata A., Maruyama M., Akagi T., Hashikawa T., Kanazawa I., Tsuji S., and Nukina N. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12 (2003) 2625-2635
22. Jakes R., Crowther R.A., Lee V.M., Trojanowski J.Q., Iwatsubo T., and Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci. Lett. 269 (1999) 13-16
23. Jellinger K.A. Lewy body-related alpha-synucleinopathy in the aged human brain. J. Neural. Transm. 111 (2004) 1219-3125
24. Kastner A., Hirsch E.C., Herrero M.T., Javoy-Agid F., and Agid Y. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. J. Neurochem. 61 (1993) 1024-1034
25. Kawamura K., Oda K., and Ishiwata K. Age-related changes of the [11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats: a PET study. Ann. Nucl. Med. 17 (2003) 249-253
26. Keller J.N., Dimayuga E., Chen Q., Thorpe J., Gee J., and Ding Q. Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int. J. Biochem. Cell Biol. 36 (2004) 2376-2391
27. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., and Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22 (2002) 2780-2791
28. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., and Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2884-2889
29. Kish SJ., Shannak K., Rajput A., Deck J.H., and Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58 (1992) 642-648
30. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
31. Klucken J., Shin Y., Masliah E., Hyman B.T., and McLean P.J. Hsp70 reduces alpha-synuclein aggregation and toxicity. J. Biol. Chem. 279 (2004) 25497-25502
32. Kompoliti K., Chu Y., Polish A., Roberts J., McKay H., Mufson E.J., Leurgans S., Morrison J.H., and Kordower J.H. Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J. Comp. Neurol. 472 (2004) 193-207
33. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przunte H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
34. Le Couture D.G., Muller M., Yang M.C., Mellick G.D., and McLean A.J. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev. Environ. Health 17 (2002) 51-64
35. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., and Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33 (2003) 85-89
36. Lee C.S., Schulzer M., Mak E., Hammerstad J.P., Calne S., and Calne D.B. Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology 45 (1995) 435-439
37. Lee H.J., Khoshaghideh F., Patel S., and Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24 (2004) 1888-1896
38. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
39. Li J., Zhu M., Rajamani S., Uversky V.N., and Fink A.L. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11 (2004) 1513-1521
40. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., and Lee M.K. Stabilization of alpha-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J. Neurosci. 24 (2004) 7400-7409
41. Lincoln S., Crook R., Chartier-Harlin MC., Gwinn-Hardy K., Baker M., Mouroux V., Richard F., Becquet E., Amouyel P., Destee A., Hardy J., and Farrer M. No pathogenic mutations in the beta-synuclein gene in Parkinson's disease. Neurosci. Lett. 269 (1999) 107-109
42. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., and Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10813-10818
43. Ma S.Y., Ciliax B.J., Stebbins G., Jaffar S., Joyce J.N., Cochran E.J., Kordower J.H., Mash D.C., Levey A.I., and Mufson E.J. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J. Comp. Neurol. 409 (1999) 25-37
44. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., and Youdim M.B. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. N. Y Acad. Sci. 1053 (2005) 356-375
45. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
46. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., and Janson A.M. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471 (2004) 387-395
47. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison Jr. R.C., and Lau Y.S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956 (2002) 156-165
48. Meredith G.E., Halliday G.M., and Totterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat. Disord. 10 (2004) 191-202
49. Miake H., Mizusawa H., Iwatsubo T., and Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 277 (2002) 19213-19219
50. Muthane U., Yasha T.C., and Shankar S.K. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann. Neurol. 43 (1998) 283-287
51. Neumann M., Muller V., Kretzschmar H.A., Haass C., and Kahle P.J. Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J. Neuropathol. Exp. Neurol. 63 (2004) 225-235
52. Nieto M., Gil-Bea F.J., Dalfo E., Cuadrado M., Cabodevilla F., Sanchez B., Catena S., Sesma T., Ribe E., Ferrer I., Ramirez M.J., and Gomez-Isla T. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 27 (2006) 848-856
53. Nishioka K., Hayashi S., Farrer M.J., Singleton A.B., Yoshino H., Imai H., Kitami T., Sato K., Kuroda R., Tomiyama H., Mizoguchi K., Murata M., Toda T., Imoto I., Inazawa J., Mizuno Y., and Hattori N. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59 (2006) 298-309
54. Ohtake H., Limprasert P., Fan Y., Onodera O., Kakita A., Takahashi H., Bonner L.T., Tsuang D.W., Murray I.V., Lee V.M., Trojanowski J.Q., Ishikawa A., Idezuka J., Murata M., Toda T., Bird T.D., Leverenz J.B., Tsuji S., and La Spada A.R. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63 (2004) 805-811
55. Pankratz N., and Foroud T. Genetics of Parkinson disease. NeuroRx 1 (2004) 235-242
56. Phinney A.L., Andringa G., Bol J.G., Wolters E.C., Muiswinkel F.L., Dam A.M., and Drukarch B. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Relat. Disord. 12 (2006) 228-238
57. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
58. Rockenstein E., Schwach G., Ingolic E., Adame A., Crews L., Mante M., Pfragner R., Schreiner E., Windisch M., and Masliah E. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J. Neurosci. Res. 80 (2005) 247-259
59. Ross G.W., Petrovitch H., Abbott R.D., Nelson J., Markesbery W., Davis D., Hardman J., Launer L., Masaki K., Tanner C.M., and White L.R. Parkinsonian signs and substantia nigra neuron density in descendents elders without PD. Ann. Neurol. 56 (2004) 532-539
60. Saito Y., Ruberu NN., Sawabe M., Arai T., Kazama H., Hosoi T., Yamanouchi H., and Murayama S. Lewy body-related alpha-synucleinopathy in aging. J. Neuropathol. Exp. Neurol. 63 (2004) 742-749
61. Sampathu DM., Giasson B.I., Pawlyk A.C., Trojanowski J.Q., and Lee V.M. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol. 163 (2003) 91-100
62. Sapru M.K., Yates J.W., Hogan S., Jiang L., Halter J., and Bohn M.C. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198 (2006) 382-390
63. Schmitz C., and Hof P.R. Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J. Chem. Neuroanat. 1 (2000) 93-114
64. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
65. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., and Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
66. Shin Y., Klucken J., Patterson C., Hyman B.T., and McLean P.J. The co-chaperone carboxyl terminus of Hsp70-interacting protein CHIP mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280 (2005) 23727-23734
67. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
68. Snyder H., and Wolozin B. Pathological proteins in Parkinson's disease: focus on the proteasome. J. Mol. Neurosci. 24 (2004) 425-442
69. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
70. Song D.D., Shults C.W., Sisk A., Rockenstein E., and Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 186 (2004) 158-172
71. Totterdell S., and Meredith G.E. Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience 135 (2005) 907-913
72. West M.J., and Gundersen H.J. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. Comp. Neurol. 296 (1990) 1-22
73. Yavich L., Tanila H., Vepsalainen S., and Jakala P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24 (2004) 11165-11170